| Autor: |
Lledó, P., Abrams, S. M. L., Johnston, A., Patel, M., Pearson, R. M., Turner, P. |
| Zdroj: |
European Journal of Clinical Pharmacology; January 1993, Vol. 44 Issue: 1 p63-67, 5p |
| Abstrakt: |
Marked interindividual variation has been observed in the pharmacokinetics of the antiarrhythmic agent mexiletine. The fact that its urinary excretion is dependent on urinary pH may account, in part, for such variation. The influence that genetic differences in hepatic metabolism of the debrisoquine-type may have on mexiletine pharmacokinetics was considered in this study. The pharmacokinetics and urinary excretion of mexiletine (250 mg administered intravenously) were investigated in 5 rapid extensive metabolisers (EM), 5 slow EM and 5 poor metabolisers (PM) of debrisoquine, under conditions of controlled urinary pH. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink